Can-fite Biopharma (CANF) news
Recent news
Corrected-Can Fite Biopharma Ltd files for offering of up to 6,589,796 ordinary shares by selling shareholders - SEC filing (adds dropped words 'by selling shareholders')
Can-Fite BioPharma Ltd. (NASDAQ: CANF) has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the potential offering of up to 6,589,796 ordinary shares by selling shareholders, according to a recent SEC filing . The registration statement, which includes a…
AInvest Wire · Sep 28, 2026Can-Fite reports Q2 2026 financial results and ongoing clinical progress highlighting longer-than-anticipated overall survival in ongoing pivotal phase III liver cancer study
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) reported financial results for the second quarter of 2026 and provided updates on its clinical programs, including encouraging data from its pivotal Phase III study of Namodenoson for the treatment of advanced hepatocellular carcinoma…
AInvest Wire · Sep 8, 2026Can-Fite Biopharma - Can-Fite evaluating earlier interim analysis for phase III Namodeno son study
AInvest Wire · Sep 2, 2026Can-Fite reports longer-than-anticipated overall survival in ongoing pivotal phase III liver cancer study
AInvest Wire · Sep 2, 2026Can-Fite Biopharma: Files $100 mln shelf registration statement with SEC - SEC filing
AInvest Wire · Aug 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.